QTRX

+ Watchlist + Portfolio

Quanterix Corp.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.41
52-Week Range: $2.15 – $8.77
Market Cap: $172.15M
P/E (TTM): —
EPS (TTM): -2.61
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.72
PEG Ratio: —
Return on Equity: -46.48%
Return on Assets: -16.67%
Gross Margin: 44.56%
Operating Margin: -68.37%
Profit Margin: -80.25%
Current Ratio: 3.40
Debt/Equity: 0.14
Total Debt: $33.39M
Free Cash Flow: $-29.92M
Revenue Growth: 34.40%
Earnings Growth: —
Enterprise Value: $112.00M

QTRX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$104.95M	$121.14M	$135.44M	$138.65M
Cost of Revenue	$60.16M	$48.14M	$54.32M	$73.94M
Gross Profit	$44.79M	$73.00M	$81.12M	$64.72M
Research & Development	$26.81M	$26.06M	$31.08M	$35.92M
Selling, General & Admin	$93.26M	$92.82M	$104.64M	$138.85M
Operating Expenses	$119.50M	$117.66M	$133.74M	$174.53M
Operating Income	-$74.71M	-$44.66M	-$52.62M	-$109.81M
EBITDA	-$68.58M	-$36.37M	-$44.26M	-$90.89M
Pretax Income	-$99.41M	-$27.64M	-$38.10M	-$112.27M
Income Tax	$164.00K	$719.00K	$434.00K	-$5.12M
Net Income	-$99.57M	-$28.35M	-$38.53M	-$107.15M
Diluted EPS	-2.61	-0.75	-1.00	-2.51
Diluted Shares	36.99M	37.59M	38.37M	42.64M

QTRX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$338.74M	$174.42M	$56.71M	$29.84M
Receivables	$19.02M	$25.41M	$32.14M	$29.97M
Inventory	$16.96M	$26.12M	$32.77M	$54.76M
Current Assets	$381.52M	$382.10M	$363.59M	$212.26M
Total Assets	$433.58M	$428.57M	$406.53M	$418.77M
Current Liabilities	$31.35M	$38.98M	$42.01M	$74.76M
Total Debt	$44.10M	$41.46M	$37.37M	$37.24M
Total Liabilities	$75.65M	$78.61M	$76.50M	$123.04M
Retained Earnings	-$403.20M	-$431.55M	-$470.08M	-$577.23M
Shareholders' Equity	$357.93M	$349.96M	$330.04M	$295.73M
Working Capital	$350.18M	$343.11M	$321.59M	$137.50M

QTRX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$48.61M	-$18.85M	-$35.16M	-$77.24M
Capital Expenditure	-$11.61M	-$3.84M	-$3.37M	-$2.61M
Free Cash Flow	-$60.23M	-$22.69M	-$38.53M	-$79.85M
Depreciation & Amortisation	$6.12M	$8.29M	$8.36M	$18.93M
Stock-Based Compensation	$15.38M	$16.82M	$19.99M	$20.72M
Investing Cash Flow	-$11.09M	-$148.45M	-$82.27M	$50.23M
Financing Cash Flow	$2.31M	$2.69M	$456.00K	-$708.00K
Net Change in Cash	-$57.39M	-$164.61M	-$116.97M	-$27.71M

QTRX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$30.33M	$24.45M	$40.15M	$43.78M	$36.41M	$32.91M
Cost of Revenue	$15.49M	$13.18M	$23.03M	$23.82M	$20.85M	$20.23M
Gross Profit	$14.84M	$10.00M	$17.12M	$19.96M	$15.57M	$12.67M
Research & Development	$10.04M	$9.08M	$8.01M	$8.80M	$7.32M	$7.82M
Selling, General & Admin	$31.17M	$31.65M	$39.35M	$35.11M	$29.77M	$27.35M
Operating Expenses	$41.20M	$40.71M	$47.27M	$43.83M	$37.09M	$35.17M
Operating Income	-$26.37M	-$29.43M	-$30.15M	-$23.87M	-$21.53M	-$22.50M
EBITDA	-$24.18M	-$26.58M	-$25.57M	-$14.56M	-$15.92M	-$14.76M
Pretax Income	-$23.42M	-$30.09M	-$36.00M	-$22.77M	-$17.55M	-$48.99M
Income Tax	-$2.91M	-$73.00K	-$2.48M	$345.00K	-$7.00K	-$54.00K
Net Income	-$20.50M	-$30.01M	-$33.52M	-$23.12M	-$17.54M	-$48.93M
Diluted EPS	-0.53	-0.77	-0.73	-0.49	-0.37	-1.04
Diluted Shares	38.72M	38.89M	46.06M	46.78M	46.98M	47.17M

QTRX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$76.51M	$132.90M	$38.30M	$29.84M	$36.18M	$44.17M
Receivables	$28.26M	$23.55M	$33.03M	$29.97M	$26.78M	$22.34M
Inventory	$31.03M	$30.14M	$54.96M	$54.76M	$50.96M	$47.60M
Current Assets	$335.00M	$322.12M	$233.28M	$212.26M	$185.72M	$171.05M
Total Assets	$396.51M	$375.61M	$444.14M	$418.77M	$366.67M	$319.63M
Current Liabilities	$40.40M	$48.20M	$77.35M	$74.76M	$49.91M	$50.37M
Total Debt	$36.41M	$35.53M	$40.12M	$37.24M	$35.34M	$33.39M
Total Liabilities	$80.12M	$83.15M	$129.61M	$123.04M	$84.53M	$82.42M
Retained Earnings	-$490.58M	-$520.60M	-$554.12M	-$577.23M	-$594.77M	-$643.71M
Shareholders' Equity	$316.39M	$292.46M	$314.53M	$295.73M	$282.14M	$237.21M
Working Capital	$294.61M	$273.92M	$155.93M	$137.50M	$135.82M	$120.68M

QTRX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$13.89M	-$5.66M	-$41.25M	-$16.44M	-$18.11M	-$5.12M
Capital Expenditure	-$1.26M	-$777.00K	-$677.00K	—	-$87.00K	-$96.00K
Free Cash Flow	-$15.14M	-$6.43M	-$41.93M	-$16.35M	-$18.19M	-$5.21M
Depreciation & Amortisation	$2.19M	$2.85M	$4.58M	$9.31M	$5.60M	$7.74M
Stock-Based Compensation	$5.46M	$5.37M	$5.47M	$4.42M	$4.53M	$4.21M
Investing Cash Flow	$32.76M	$61.88M	-$52.85M	$8.44M	$25.26M	$13.66M
Financing Cash Flow	$93.00K	-$429.00K	$150.00K	-$522.00K	-$770.00K	-$527.00K
Net Change in Cash	$18.97M	$55.80M	-$93.95M	-$8.53M	$6.39M	$8.02M

Market Snapshot

About

Quanterix has pioneered ultra-sensitive biomarker detection using its proprietary Simoa (Single Molecule Array) technology. The platform enables measurement of proteins at extremely low concentrations in blood, advancing early disease detection, drug development, and precision medicine. Quanterix serves pharmaceutical, clinical research, and diagnostic markets with instruments, consumables, and testing services.